GENT Key Stats
- Update on Gentium's Defibrotide Jun 10
- Update on Gentium's Defibrotide - Analyst Blog Zacks Jun 10
- InPlay: Gentium files documentation requesting a Re-examination of the negative ... Jun 4
- Gentium Provides Update on Re-Examination of Defibrotide MAA to EMA GlobeNewswire Jun 4
- BMRN's Vimizim Under Review May 31
- BMRN's Vimizim Under Review - Analyst Blog Zacks May 31
- Gentium SpA Stock Upgraded (GENT) May 29
- Gentium (GENT) Swings to Q1 Profit Street Insider May 14
- Q1 2013 Gentium SpA Earnings Release - 07:00 am ET May 14
- Gentium Reports First Quarter Financial Results GlobeNewswire May 14
GENT Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Gentium is down 22.15% over the last year vs S&P 500 Total Return up 23.89%, Salix Pharmaceuticals up 24.14%, and Takeda Pharmaceutical up 10.76%.
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Pro Ratings for GENT
Pro Strategies Featuring GENT
Did Gentium make it into our Pro Portfolio Strategies?
Start your YCharts Pro membership now to find out.